シンポジウム1 「喉頭気管乳頭腫の最前線」
喉頭乳頭腫に対するシドフォビルの有効性と安全性
2021 年 33 巻 02 号 p. 82-85
詳細
2021 年 33 巻 02 号 p. 82-85
Objectives : The treatment of recurrent respiratory papillomatosis (RRP) continues to be difficult. We evaluated the benefits and risks of the intralesional administration of cidofovir for severe RRP in 13 patients.
Methods : Thirteen patients received intralesional cidofovir. The surgeries were performed three times every two weeks, with intralesional injections of cidofovir (7.5 mg/ml). A further endoscopic evaluation was made at three months depending on whether there was persistent papillomatosis. The intrelesional injection of cidofovir with CO2 laser vaporization was performed in the case of persistent papilloma, and treatment was repeated as long as papillomas were observed.
Results : One of 13 patients achieved complete remission and seven achieved partial remission. Five patients showed a poor response to cidofovir. No side effects related to cidofovir were observed in 13 patients.
Conclusion : The results of the study indicate that the intralesional injection of cidofovir can be an effective treatment method for recurrent respiratory papillomatosis.
